# OnCo record paper-act-in-sarc-lancet-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-act-in-sarc-lancet-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-act-in-sarc-lancet-oncol-2019" ;
  schema:name "NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial"@en ;
  schema:description "The primary report of Act.In.Sarc: a single injection of hafnium oxide nanoparticles before preoperative radiotherapy doubled the share of sarcomas with a pathological complete response, from 8 to 16 percent."@en ;
  schema:url <https://onco.cc/key-papers/paper-act-in-sarc-lancet-oncol-2019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(19)30326-2>, <https://pubmed.ncbi.nlm.nih.gov/31296491/>, <https://clinicaltrials.gov/study/NCT02379845> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(19)30326-2> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Bonvalot S, Rutkowski PL, Thariat J, et al." ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/radiosensitisers/> ;
  onco:drugs <https://onco.cc/drugs/nbtxr3/> ;
  onco:companies <https://onco.cc/companies/nanobiotix/> ;
  onco:trials <https://onco.cc/trials/act-in-sarc/> ;
  onco:people <https://onco.cc/people/sylvie-bonvalot/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .